Anastasia Stefania Alexopoulos, MBBS

Assistant Professor of Medicine
Email address anastasia.alexopoulos@duke.edu

Education and Training

  • Fellowship, Endocrinology, Brigham and Women's Hospital, 2017 - 2018
  • Residency, Internal Medicine, Emory University School of Medicine, 2013 - 2016
  • M.B.B.S., Imperial College London (United Kingdom), 2012

Publications

Alexopoulos, Anastasia-Stefania, Ryan Duffy, Elizabeth A. Kobe, Jashalynn German, Cynthia A. Moylan, Diana Soliman, Amy S. Jeffreys, Cynthia J. Coffman, and Matthew J. Crowley. “Underrecognition of Nonalcoholic Fatty Liver Disease in Poorly Controlled Diabetes: A Call to Action in Diabetes Care.” J Endocr Soc 5, no. 12 (December 1, 2021): bvab155. https://doi.org/10.1210/jendso/bvab155.

PMID
34755002
Full Text

Alexopoulos, Anastasia-Stefania, William S. Yancy, David Edelman, Cynthia J. Coffman, Amy S. Jeffreys, Matthew L. Maciejewski, Corrine I. Voils, et al. “Clinical associations of an updated medication effect score for measuring diabetes treatment intensity.” Chronic Illn 17, no. 4 (December 2021): 451–62. https://doi.org/10.1177/1742395319884096.

PMID
31653175
Full Text

Alexopoulos, Anastasia-Stefania, Anna R. Kahkoska, Virginia Pate, Marie C. Bradley, Joshua Niznik, Carolyn Thorpe, Til Stürmer, and John Buse. “Deintensification of Treatment With Sulfonylurea and Insulin After Severe Hypoglycemia Among Older Adults With Diabetes.” Jama Netw Open 4, no. 11 (November 1, 2021): e2132215. https://doi.org/10.1001/jamanetworkopen.2021.32215.

PMID
34726745
Full Text

Alexopoulos, Anastasia-Stefania, Matthew J. Crowley, Ying Wang, Cynthia A. Moylan, Cynthia D. Guy, Ricardo Henao, Dawn L. Piercy, et al. “Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease.” Hepatology 74, no. 3 (September 2021): 1220–33. https://doi.org/10.1002/hep.31806.

PMID
33724511
Full Text

Alexopoulos, Anastasia-Stefania, Andreas Andersen, Anders Meller Donatsky, Amoolya Gowda, and John B. Buse. “Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100.” Diabetes Obes Metab 23, no. 8 (August 2021): 1983–88. https://doi.org/10.1111/dom.14397.

PMID
33830626
Full Text

Kobe, Elizabeth A., Clarissa J. Diamantidis, Hayden B. Bosworth, Clemontina A. Davenport, Megan Oakes, Anastasia-Stefania Alexopoulos, Jane Pendergast, Uptal D. Patel, and Matthew J. Crowley. “Racial Differences in the Effectiveness of a Multifactorial Telehealth Intervention to Slow Diabetic Kidney Disease.” Med Care 58, no. 11 (November 2020): 968–73. https://doi.org/10.1097/MLR.0000000000001387.

PMID
32833935
Full Text

Yang, Jeff Y., Andrew M. Moon, Hannah Kim, Virginia Pate, A Sidney Barritt, Matthew J. Crowley, John B. Buse, Til Stürmer, and Anastasia-Stefania Alexopoulos. “Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes.” J Diabetes Complications 34, no. 11 (November 2020): 107706. https://doi.org/10.1016/j.jdiacomp.2020.107706.

PMID
32843283
Full Text

Sagalla, Nicole, William S. Yancy, David Edelman, Amy S. Jeffreys, Cynthia J. Coffman, Corrine I. Voils, Anastasia-Stefania Alexopoulos, Matthew L. Maciejewski, Moahad Dar, and Matthew J. Crowley. “Factors associated with non-adherence to insulin and non-insulin medications in patients with poorly controlled diabetes.” Chronic Illn, October 25, 2020, 1742395320968627. https://doi.org/10.1177/1742395320968627.

PMID
33100020
Full Text

Yang, Jeff Y., Anastasia Alexopoulos, Andrew M. Moon, Hannah Kim, Virginia Pate, A Sidney Barritt, Til Sturmer, and John B. Buse. “Newer second-line glucose-lowering drugs versus thiazolidinediones and cirrhosis risk in type 2 diabetes.” In Pharmacoepidemiology and Drug Safety, 29:606–606, 2020.

Scholars@Duke

Crowley, Matthew J., Darren K. McGuire, Anastasia-Stefania Alexopoulos, Thomas Jon Jensen, Søren Rasmussen, Hans A. Saevereid, Subodh Verma, and John B. Buse. “Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial.” Diabetes Care 43, no. 9 (September 2020): e108–10. https://doi.org/10.2337/dc20-0437.

PMID
32647053
Full Text

Pages